Semaglutide vs Tirzepatide: Mechanism, Trial Data, Which to Choose

Semaglutide (Ozempic / Wegovy) and Tirzepatide (Mounjaro / Zepbound) are the two leading FDA-approved peptide drugs for weight loss and type 2 diabetes. Tirzepatide adds GIP-receptor agonism on top of GLP-1, producing a larger mean weight-loss effect (~21% vs ~15% at maintenance) with broadly similar tolerability. This article covers the head-to-head: mechanism, trial data, side effects, cardiovascular evidence, and how to decide.

For the broader weight-loss landscape, see peptides for weight loss. For per-drug profiles, see Semaglutide and Tirzepatide.

Quick verdict table

	Semaglutide	Tirzepatide
Brand names	Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D)	Mounjaro (T2D), Zepbound (obesity)
Mechanism	GLP-1 receptor agonist	GIP + GLP-1 dual receptor agonist
FDA approval (US)	2017 (T2D), 2021 (obesity)	2022 (T2D), 2023 (obesity)
Trial weight loss (best read)	~15% at 68 weeks (STEP 1)	~21% at 72 weeks (SURMOUNT-1)
Dose schedule	Weekly SC	Weekly SC
Titration window	16+ weeks	16+ weeks
Common side effects	Nausea, vomiting, diarrhea, constipation	Same; often milder at matched-efficacy dose
CV outcome data	SELECT: 20% MACE reduction	SURPASS-CVOT reads 2026–2027
Oral option?	Yes (Rybelsus, lower efficacy)	No
Cost (cash-pay, US)	$900–$1,400/month	$1,000–$1,400/month

Mechanism

Semaglutide

A GLP-1 receptor agonist. Mimics the body's natural glucagon-like peptide-1, which is released from intestinal L-cells after eating. The receptor is expressed in the pancreas (drives glucose-dependent insulin release), the stomach (slows gastric emptying), and the brain (suppresses appetite via central pathways). Native GLP-1 has a ~2-minute half-life; Semaglutide is engineered for ~1-week half-life via fatty-acid attachment that binds it to serum albumin.

Tirzepatide

A dual agonist that binds both the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic peptide) is released from intestinal K-cells; the receptor modulates insulin response and lipid metabolism. The GIP-receptor mechanism on its own does not reliably produce weight loss in trials, but the combination with GLP-1 is synergistic — meaningfully larger weight loss than GLP-1 alone at comparable tolerability.

Trial data

Semaglutide — STEP program

STEP-1 (the headline trial for the obesity indication): 1,961 adults with overweight/obesity but without T2D, randomized to Semaglutide 2.4 mg weekly or placebo. At 68 weeks:

• Mean weight loss: ~15% in the Semaglutide arm vs ~2% placebo.
• ~32% of patients lost ≥20% of body weight.
• Cardiometabolic markers (waist circumference, BP, lipid panel, A1C) improved.

STEP-2 (T2D cohort): smaller weight-loss effect (~10%) at the same trial duration. T2D patients consistently lose less on GLP-1s than non-diabetic patients.

Tirzepatide — SURMOUNT and SURPASS programs

SURMOUNT-1 (the headline trial for the Zepbound obesity indication): 2,539 adults with obesity but without T2D. At 72 weeks:

• Mean weight loss: ~21% at the 15 mg weekly dose.
• ~57% of patients lost ≥20% of body weight.
• Even larger cardiometabolic improvements than STEP-1.

SURMOUNT-2 (T2D cohort): ~15% weight loss at 72 weeks — meaningfully larger than Semaglutide in T2D.

SURPASS-2 (head-to-head vs Semaglutide in T2D): Tirzepatide produced larger weight loss AND larger A1C reduction at matched-cohort comparisons.

Bottom line on efficacy

Tirzepatide is larger at every measured endpoint that overlaps. The magnitude difference is real and clinically meaningful.

Side effects

Both drugs have GI-dominated side-effect profiles. The patterns:

Common (≥10% in trials, both drugs):

• Nausea, vomiting, diarrhea, constipation, reduced appetite (often desired), injection-site reactions.

Differences:

• Tirzepatide is often described as "better tolerated at matched-efficacy doses" — i.e., at the dose required to produce equivalent weight loss, Tirzepatide produces fewer GI side effects. At maximum doses both drugs have similar discontinuation rates.
• Hair shedding is reported in a fraction of users on both drugs (poorly characterized but real).
• Fatigue early in titration on both.

Boxed warning (both drugs):

• Thyroid C-cell tumor risk (rodent finding; human signal not established).
• Contraindicates use in patients with personal or family history of medullary thyroid carcinoma or MEN2.

Less common but notable (both drugs):

• Pancreatitis (single-digit per 1000 patient-years).
• Gallbladder disease (more common during rapid weight loss).
• Muscle-mass loss alongside fat loss (20–40% of total weight lost). Mitigation: resistance training + protein-prioritized diet.

See peptide side effects for the full class summary.

Cardiovascular outcome evidence

Semaglutide — SELECT trial (2023, ~17,000 patients with established CVD and overweight/obesity but without T2D):

• 20% relative reduction in major adverse cardiovascular events (MACE).
• The trial established Semaglutide as a cardio-protective drug independent of its diabetes indication.
• FDA added the CV benefit to the Wegovy label in 2024.

Tirzepatide — SURPASS-CVOT:

• The Phase 3 cardiovascular outcomes trial is ongoing. Reads expected 2026–2027.
• Until those results land, Tirzepatide does not have FDA-labeled CV benefit even though the metabolic-marker improvements suggest it likely will.

For patients with established cardiovascular disease today, this is a real factor — Semaglutide has the documented CV benefit; Tirzepatide does not yet.

Cost and insurance

US list prices for both drugs are roughly $1,000–$1,400/month before insurance.

Insurance coverage has improved through 2024–2026 but varies sharply:

• Employer plans increasingly cover one or both, often with a BMI ≥ 30 requirement or a comorbidity requirement.
• Manufacturer discount programs (Novo's WeGoTogether, Lilly's Zepbound savings card) reduce cash-pay by $100–$300/month for eligible patients.

See peptide therapy cost for the full pricing breakdown.

How to choose

A decision frame:

• You have type 2 diabetes alongside obesity? Tirzepatide has the stronger T2D weight-loss and A1C data (SURPASS-2 head-to-head).
• You have established cardiovascular disease? Semaglutide has the documented CV benefit (SELECT). Wait for SURPASS-CVOT to confirm Tirzepatide.
• You want the largest possible weight loss from a currently-approved drug? Tirzepatide.
• You can't tolerate Semaglutide? Tirzepatide is often better tolerated at matched-efficacy doses.
• You need an oral option? Semaglutide (Rybelsus) has the only currently-approved oral GLP-1; Orforglipron (oral, non-peptide) is awaiting FDA decision.
• Cost is the binding constraint? Whichever your insurance covers better.
• You want the longest track record? Semaglutide — 2017 T2D approval; the most post-marketing data.

What about Retatrutide and CagriSema?

Both are in Phase 3 and produce larger weight loss numbers in early data than either Semaglutide or Tirzepatide (Retatrutide ~24% Phase 2; CagriSema ~22% in REDEFINE-1).

Neither is FDA-approved yet. Realistic clinical availability is 2027 at the earliest.

See Retatrutide explained and Cagrilintide explained.

What happens when you stop

Both drugs produce substantial weight regain within 12–24 months of stopping in the absence of behavioral change. This is a feature of the mechanism, not a failure of the drug — appetite signals revert when the drug clears.

Plan for continuation as part of the decision frame. Neither drug is a "course" you complete.

Where to go from here

• Peptides for weight loss — broader pillar with the full landscape.
• Best peptides for fat loss — ranked roundup.
• Peptide therapy, peptide therapy cost — clinical-program side.
• Per-peptide profiles: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide.
• Are peptides safe?, peptide side effects — safety frame.

This is informational, not medical advice. Both drugs require clinician supervision. Speak to a licensed provider before starting.